RN

Rajeshriben Navishbhai Shah

Active Director Designated Partner DIN 11363252
DIN 11363252 First appointment Nov 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Rajeshriben Navishbhai Shah

Data last updated:

Rajeshriben Navishbhai Shah is a Designated Partner at Aumax Bioscience Pharmaceutical Llp (since 2025).

DIN 11363252
Primary Designation Designated Partner
First Appointment 01 Nov 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner01 Nov 20252025Active

Board colleagues of Rajeshriben Navishbhai Shah

Directorship timeline

Open interactive timeline →
Aumax Bioscience Pharmaceutical Llp
Premium access

Shareholding and investment profile for Rajeshriben Navishbhai Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rajeshriben Navishbhai Shah

Rajeshriben Navishbhai Shah currently holds 1 directorship: Aumax Bioscience Pharmaceutical Llp (Designated Partner, since 01 Nov 2025).

Rajeshriben Navishbhai Shah was first appointed on 01 Nov 2025 as Designated Partner at Aumax Bioscience Pharmaceutical Llp.

The current boards of Rajeshriben Navishbhai Shah's companies include Chetankumar Jayantilal Rathod (Aumax Bioscience Pharmaceutical Llp), Divyarajesinh Digvijaysinh Jadeja (Aumax Bioscience Pharmaceutical Llp), Krunalkumar Punamchand Prajapati (Aumax Bioscience Pharmaceutical Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available